|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that the reduction of Cebpa gene expression in Lck-CALM/AF10 mice did not affect their hematopoiesis or induce leukemia.
|
31141090 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
|
30679799 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functionally, we confirmed that diminished expression of PU.1 or genetic deletion of C/EBPα in MLL-AF9 cells generates resistance of these leukemias to LSD1 inhibition.
|
29453291 |
2018 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial CEBPA-mutated acute myeloid leukemia (AML) represents a recognized leukemia predisposition syndrome, with several families described in the literature since the initial report in 2004.
|
28637622 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In most cases, miR-9 and miR-9* were significantly upregulated and their expression levels varied according to AML subtype, with the highest expression in MLL-related leukemias harboring 11q23 abnormalities and the lowest expression in AML cases with t(8;21) and biallelic mutations in CEBPA.
|
26174629 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Essential HOXA9 cofactors and collaborators are also being identified, including transcription factors PU.1 and C/EBPα, which are required for HOXA9-driven leukemia.
|
27258906 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
|
26996668 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study examines the genetic events initiating leukemia and details the clinical progression of disease across multiple families harboring germ-line CEBPA mutations.
|
26162409 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the prognostic role of myeloid transcription factor gene CEBPA (CCAAT/enhancer binding protein-α), a novel gene involved in leukemia in Egyptian adults AML.
|
22990006 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sox4you: a new player in C/EBPα leukemia.
|
24229703 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subtyping of acute myeloid leukemia requires an integration of information from the patient's clinical history (such as any prior preleukemic myeloid neoplasm or cytotoxic potentially leukemogenic therapy), the leukemia morphology, cytogenetic findings, and the mutation status of particular genes (NPM1, FLT3, and CEBPA).
|
23590662 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results show that in contrast to its classical role antagonizing trithorax function, the polycomb group protein EZH2 collaborates with trithorax-associated menin to block MLL-AF9 leukemia cell differentiation, uncovering a novel mechanism for suppression of C/EBPα and leukemia cell differentiation, through menin-mediated upregulation of EZH2.
|
23349306 |
2013 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate that Sox4 overexpression resulting from C/EBPα inactivation contributes to the development of leukemia with a distinct LIC phenotype.
|
24183681 |
2013 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
|
22766221 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, treatment of these leukemias with demethylating agents restored the C/EBPα-C/EBPγ balance and upregulated the expression of myeloid differentiation markers.
|
23160200 |
2012 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results provide the first report of multiple mutations of CEBPA contributing to the transformation of donor cells to the leukemic phenotype and provide clues to support the multiple-genetic-hits mechanism of donor cell leukemia.
|
21403128 |
2011 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In this review we will discuss and summarize briefly our current knowledge of epigenetic alterations in leukemias and will turn our attention to a concrete example of epigenetic deregulation of CCAAT/enhancer-binding protein alpha (C/EBPα), a key regulator for granulocytic differentiation of common myeloid progenitor cells in order to highlight the cooperativity of genetic and epigenetic mechanisms acting on this gene during the process of leukemogenesis.
|
21601364 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, DNA methylation profiles segregated patients with CEBPA aberrations from other subtypes of leukemia, defined four epigenetically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11, and PML-RARA leukemia entities are associated with specific methylation profiles.
|
20060365 |
2010 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, these studies indicate that CEBPA mutations affect HSCs in early leukemia development by inducing proliferation and limiting their lineage potential.
|
20422469 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biologically, CEBPA-silenced leukemias presented with a decreased response to myeloid growth factors in vitro.
|
19168792 |
2009 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
|
18729193 |
2008 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
We found that in these leukemias, the CEBPA gene was silenced, which was associated with frequent promoter hypermethylation.
|
17671232 |
2007 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The close relationship of CEBPA mutations with the leukemia status of the patients and the concordance of mutation in presenting and relapse samples implicate the CEBPA mutation as a potential marker for monitoring minimal residue disease.
|
15746035 |
2005 |